We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-9.52%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$985M
AUM Growth
-$142M
Cap. Flow
+$49.9M
Cap. Flow %
5.07%
Top 10 Hldgs %
58.04%
Holding
76
New
11
Increased
24
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$54.6M
2
PCVX icon
Vaxcyte
PCVX
+$34.3M
3
GKOS icon
Glaukos
GKOS
+$21.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21.2M
5
CYH icon
Community Health Systems
CYH
+$17.5M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$38M
2
INSP icon
Inspire Medical Systems
INSP
+$19.5M
3
VTRS icon
Viatris
VTRS
+$15.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
5
EW icon
Edwards Lifesciences
EW
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 11.4%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47B
$126M 12.84%
893,721
+16,955
+2% +$2.73M
GSK icon
2
GSK
GSK
$102B
$102M 10.32%
2,623,246
-1,038,522
-28% -$38M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$489B
$58M 5.89%
123,600
-119,500
-49% -$60.7M
HCA icon
4
HCA Healthcare
HCA
$90.5B
$52.7M 5.35%
152,502
-23,306
-13% -$7.5M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.74B
$51.7M 5.26%
4,212,270
+3,868,870
+1,127% +$54.6M
VERA icon
6
Vera Therapeutics
VERA
$2.46B
$45.6M 4.63%
1,898,804
+298,789
+19% +$9.6M
SPY icon
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$43M 4.37%
76,900
+47,100
+158% +$27.7M
RVTY icon
8
Revvity
RVTY
$14.4B
$31.6M 3.21%
299,087
-93,431
-24% -$10.8M
HQY icon
9
HealthEquity
HQY
$7.97B
$31.1M 3.16%
351,976
-34,721
-9% -$3.56M
INSP icon
10
Inspire Medical Systems
INSP
$1.78B
$29.7M 3.02%
186,425
-107,877
-37% -$19.5M
PTGX icon
11
Protagonist Therapeutics
PTGX
$9.34B
$26.5M 2.69%
547,116
-131,671
-19% -$5.52M
CYH icon
12
Community Health Systems
CYH
$413M
$22.8M 2.32%
8,458,020
+5,631,020
+199% +$17.5M
ZIMV
13
DELISTED
ZimVie
ZIMV
$22.5M 2.28%
2,079,380
+8,600
+0.4% +$113K
TEVA icon
14
Teva Pharmaceuticals
TEVA
$42.5B
$21.7M 2.2%
1,410,765
-831,360
-37% -$14.9M
PCVX icon
15
Vaxcyte
PCVX
$8.9B
$21M 2.14%
557,070
+429,482
+337% +$34.3M
BRKR icon
16
Bruker
BRKR
$8.7B
$20.8M 2.12%
499,207
+264,273
+112% +$13.7M
CNC icon
17
Centene
CNC
$32B
$20.7M 2.1%
340,339
+151,846
+81% +$9.18M
VRDN icon
18
Viridian Therapeutics
VRDN
$2.61B
$18.6M 1.89%
1,377,674
+597,676
+77% +$10.2M
NBIX icon
19
Neurocrine Biosciences
NBIX
$15.7B
$18.5M 1.88%
+167,243
New +$21.2M
UTHR icon
20
United Therapeutics
UTHR
$22.1B
$17.7M 1.8%
57,489
+13,786
+32% +$4.72M
TECH icon
21
Bio-Techne
TECH
$11.3B
$16.4M 1.67%
280,117
-19,193
-6% -$1.3M
BCRX icon
22
BioCryst Pharmaceuticals
BCRX
$2.51B
$16.3M 1.65%
2,172,436
+192,124
+10% +$1.55M
GKOS icon
23
Glaukos
GKOS
$10.6B
$15.6M 1.59%
+158,957
New +$21.2M
IONS icon
24
Ionis Pharmaceuticals
IONS
$10.1B
$15.6M 1.58%
517,021
+302,069
+141% +$9.89M
TVTX icon
25
Travere Therapeutics
TVTX
$6.19B
$14.6M 1.49%
816,254
+325,958
+66% +$6.62M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Eversept Partners held 76 positions worth $985M, down 13% from $1.13B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Eversept Partners deployed $49.9M of net new capital in Q1 2025, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Glaukos: 158,957 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was GSK, an estimated $38M trimmed.

  • Eversept Partners's largest Q1 2025 buy was Glaukos: 158,957 shares worth $15.6M.
  • Eversept Partners added most to Syndax Pharmaceuticals in Q1 2025, an estimated $54.6M increase.
  • Eversept Partners's biggest Q1 2025 reduction was GSK, cutting an estimated $38M.
  • Eversept Partners fully exited Viatris in Q1 2025, selling an estimated $15.8M.
  • Eversept Partners's ten largest holdings make up 58% of its $985M portfolio in Q1 2025.
  • Eversept Partners opened 11 new positions and closed 19 in Q1 2025.
  • Eversept Partners's portfolio value fell 13% quarter-over-quarter to $985M.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.